Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC

Key clinical point: Nivolumab every 4 weeks appeared comparable with every 2-week dosing in non–small cell lung cancer.

Major finding: The 6-month progression-free survival rates were 72% with each dosing regimen.

Study details: A randomized phase 3/4 trial in 363 patients with advanced non–small cell lung cancer.

Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Garon reported receiving research support from Bristol-Myers Squibb and others and consulting fees from Dracen Pharmaceuticals.

Citation:

Garon EB et al. ASCO-SITC, Abstract 100.